Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241412 | 0.86 | SMN1; SMN2 (0.38) | NPC1RAB9AMITFALDH1A1HPGD | |
| SCHEMBL10841005 | 0.85 | NPC1 (0.39) | NPC1RAB9AMITFALDH1A1HPGD | |
| SCHEMBL3266678 | 0.84 | MEN1 (0.41) | NPC1RAB9AMITFALDH1A1HPGD | |
| SCHEMBL7240870 | 0.81 | NPC1 (0.41) | NPC1RAB9AMITFALDH1A1HPGD | |
| SCHEMBL15456828 | 0.81 | MYC (0.41) | RAB9AALDH1A1HPGDSMN1; SMN2MEN1 | |
| SCHEMBL7035188 | 0.81 | SMN1; SMN2 (0.37) | NPC1RAB9AMITFALDH1A1NOTUM | |
| SCHEMBL27711169 | 0.80 | P2RX4 (0.42) | NPC1RAB9AMITFALDH1A1HPGD | |
| SCHEMBL3375350 | 0.77 | BCHE (0.44) | NPC1RAB9AALDH1A1NOTUMSMN1; SMN2 | |
| SCHEMBL6110762 | 0.76 | P2RX4 (0.46) | NPC1RAB9AALDH1A1HPGDNOTUM | |
| SCHEMBL5670700 | 0.76 | BCHE (0.46) | NOTUMMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109843298-A | The combination treatment of utilization method Buddhist nun ester X receptor (FXR) regulator | 阿卡纳治疗学有限公司 | 2019-06-04 | — | — | CN | claimed |
| CN-1458840-A | Pharmaceutical composition of cholesteryl ester transfer protein inhibitor | PFIZER PROD INC (US) | 2003-11-26 | — | — | CN | claimed |
| CN-119954828-A | Parallel ring compound and preparation and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-116322699-B | Parallel ring compound and preparation and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-02-11 | — | — | CN | disclosed |
| EP-4392425-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | Impact Therapeutics (Shanghai), Inc. (CN) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024109671-A1 | CAS9 PROTEIN, VARIANTS, OR HOMOLOGUES THEREOF-SPECIFIC PROTAC DEGRADERS AND USES THEREOF | GLUETACS THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2024-05-30 | — | — | WO | disclosed |
| WO-2023241627-A1 | CDK8/19 DUAL INHIBITORS AND METHODS OF USE THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023198195-A1 | CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST | MABSOFT THERAPEUTICS (SHANGHAI) CO., LTD. (CN) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023169226-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND THE USE THEREOF | Impact Therapeutics (Shanghai), Inc (CN) | 2023-09-14 | — | — | WO | disclosed |
| CN-116322699-A | Parallel ring compound and preparation and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2023-06-23 | — | — | CN | disclosed |
| WO-2023025307-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AS PARP INHIBITORS AND USE THEREOF | IMPACT THERAPEUTICS (SHANGHAI) , INC (CN) | 2023-03-02 | — | — | WO | disclosed |
| CN-1625397-A | Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor | PFIZER PROD INC (US) | 2005-06-08 | — | — | CN | disclosed |
| US-20050020624-A1 | Dihydroindole and tetrahydroquinoline derivatives | AEBI JOHANNES (CH) | 2005-01-27 | — | — | US | disclosed |
| CN-1545421-A | Pharmaceutical composition comprising a low-solubility and/or acid-sensitive drug and a neutralized acidic polymer | �Ʒ� | 2004-11-10 | — | — | CN | disclosed |
| US-6706751-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | HOFFMAN-LA ROCHE INC. | 2004-03-16 | — | — | US | disclosed |
| CN-1468241-A | Heterocyclic compounds as ligands of the gabaa receptor | — | 2004-01-14 | — | — | CN | disclosed |
| CN-1458840-A | Pharmaceutical composition of cholesteryl ester transfer protein inhibitor | PFIZER PROD INC (US) | 2003-11-26 | — | — | CN | disclosed |
| WO-2003014115-A1 | 3-SUBSTITUTED PYRROLO (2.1-A) ISOQUINOLINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2003-02-20 | — | — | WO | disclosed |
| WO-1993012091-A1 | D- AND L-1,2,3,4-TETRAHYDRO-ISOQUINOLINE-1-CARBOXYLIC ACIDS AND THEIR DERIVATIVES CONTAINING URETHANE-TYPE N-PROTECTING GROUPS AS WELL AS A PROCESS FOR PREPARING THEM AND THE CORRESPONDING RACEMATES | Gyógyszerkutató Intézet Kft. (HU) | 1993-06-24 | — | — | WO | disclosed |
| US-4847375-A | Antibacterial 1,8-bridged 4-quinoline-3-carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020624-A1 | Dihydroindole and tetrahydroquinoline derivatives | CYP46A1, LSS, CYP51A1 | NPC1 171/4885RAB9A 1287/4885MITF 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.